Skip to main content
. 2016 Jul 6;7(29):44950–44965. doi: 10.18632/oncotarget.10440

Figure 6. Podocyte damage is observed following MMS treatment in AagTg/Parp1−/− mice.

Figure 6

A. Immunofluorescence staining of WT1-positive podocytes in WT and AagTg/Parp1−/− mice, untreated and 14 days following MMS treatment (75 mg/kg). A representative image of n = 3 mice is shown. Magnification is 600X (scale bar 10 μm). B. Quantitation of podocytes (the % of cells stained with both WT1 and DAPI/total number of DAPI positive cells in the glomerulus) is shown. Eight glomeruli were counted on each section from n = 3-4 mice/condition. C. Immunofluorescence staining of Podocin in WT and AagTg/Parp1−/− mice in untreated and 14 days following MMS treatment (75 mg/kg). Magnification is 600X (scale bar 10 μm). D. Transmission electron microscopy (TEM) of WT and AagTg/Parp1−/− mice, untreated and 14 days following MMS treatment (75 mg/kg). P, podocytes; fp, foot processes; cl, capillary lumen; B, Bowman's capsule; GBM, glomerular basement membrane; PEC, parietal epithelial cell.